Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Soliris (eculizumab) / AstraZeneca

PREVENT, NCT01892345 / 2013-001150-10: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO ( Study)

	Safety data from PREVENT study
	Sep 2018 - Sep 2018: Safety data from PREVENT study

Terminated

143

Japan, US, Europe, RoW

Eculizumab, Soliris, Placebo

Alexion Pharmaceuticals

Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder

07/18

NCT02003144 / 2013-001151-12: An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Completed

119

Europe, Canada, Japan, US, RoW

eculizumab, Soliris

Alexion Pharmaceuticals

Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder

07/21

2019-001829-26: A Trial to Evaluate the Safety and Activity of Eculizumab in PediatricPatients with Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Ensayo para evaluar la seguridad y actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante

Not yet recruiting

2/3

Europe

Soliris, Soliris, Concentrate for solution for infusion, Soliris

Alexion Pharmaceuticals Inc., ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Diseases [C] - Nervous System Diseases [C10]

ECU-NMO-303, NCT04155424: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Terminated

2/3

Europe, Canada, Japan, US, RoW

Eculizumab, Soliris

Alexion Pharmaceuticals, Inc.

Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder

07/23



	Diseases Companies Products Productz Mechanisms of Action Sites